DaVita Inc.
NYSEDaVita enters the week after earnings on a completely different footing than it started — a Deutsche Bank upgrade to Buy with a $220 target has reset the debate on a stock that most of the Street had treated as dead money. Q1 results dropped Tuesday evening and they were unambiguous. Adjusted EPS of $2.87 beat the $2.32 consensus by a wide margin. Revenue of $3.416 billion cleared…
Snapshot as of 6 May 2026
DaVita enters the week after earnings on a completely different footing than it started — a Deutsche Bank upgrade to Buy with a $220 target has reset the debate on a stock that most of the Street had treated as dead…
DaVita enters its May 5 Q1 2026 earnings report with a notable and consistent insider-selling signal — every transaction logged over the 90-day window has been a sale, not a buy. On March 13, multiple senior executives…
DVA heads into its May 1 Q1 results carrying one of the more charged setups in health care services — a meaningful short position, a Berkshire anchor, and the shadow of February's explosive earnings gap. Short sellers…
DaVita Inc. reports Q1 results after the bell on May 1 carrying a specific burden: the last time it posted earnings, shorts fled the stock and the price ripped more than 23% in a single session — and the Street hasn't…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DVA — free to start on ORTEX.
Sign up for free →Open DVA on ORTEX